comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 16:25:40 - browse：57891

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Abortion clinic in Cancun will cater to Americans

hotspot

WSS

More doctors should go into startup world

FDA approves potent Eli Lilly obesity drug, Zepbound

Bristol 'take

A clever new way to fix Medicaid and graduate medical education

Biotech incubator Curie.Bio graduates its first startup

VC firm General Catalyst wants to buy a health system

focus

comprehensive

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Walensky prepares to leave CDC — and Congress — behind

Extreme heat events are a public health emergency

The cancer drug shortage isn’t new — and neither are the solutions

Analysis of telehealth claims data suggest service duplication

The high cost of giving birth even with insurance

Study: New antibiotic targets gonorrhea as well as last existing drug

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

focus

UCSF medical school apologizes for unethical prisoner experiments

Liquid biopsy for lung cancer is launched by Delfi

Sanofi CEO defends move to abandon profit guidance, boost research

Will General Catalyst be the first of many hospital takeovers?

Sana to lay off nearly a third of staff, de

VC firm General Catalyst wants to buy a health system

leisure time

hotspot

hotspot

focus